P/S ratio for Onconova Therapeutics (ONTX)

P/S ratio on June 5, 2024 (TTM) : 92.5

According to Onconova Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.48. At the end of 2024 the company had a P/S ratio of 93.9.

P/S ratio history for Onconova Therapeutics from 2013 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	93.9	35.46%
2023	69.3	15.9%
2022	59.8	-74.64%
2021	236	-36.8%
2020	373	1812.12%
2019	19.5	100.05%
2018	9.75	-52.51%
2017	20.5	641.98%
2016	2.77	30.1%
2015	2.13	-97.62%
2014	89.3	72.14%
2013	51.9

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Spectrum Pharmaceuticals SPPI	8.22	-91.12%	🇺🇸 USA
Array Technologies ARRY	0.9148	-99.01%	🇺🇸 USA
Baxter BAX	1.13	-98.78%	🇺🇸 USA
CTI BioPharma CTIC	15.8	-82.90%	🇺🇸 USA
Cleveland BioLabs CBLI	N/A	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions